Alpha 2.0
Login Register
» Articles » PMID: 36777985

Improving Drug Therapy for Pediatric Patients: Unfinished History of Pediatric Drug Development

Overview
Journal J Pediatr Pharmacol Ther
Specialty Pediatrics
Date 2023 Feb 13
PMID 36777985
Authors
Robert M Ward
Affiliations
Soon will be listed here.
Citing Articles

Commentary: The Injustice of Paediatric Drug Labelling in Canada - A Call to Action.

Lewis T Healthc Policy. 2023; 19(1):65-70.

PMID: 37695708 PMC: 10519341. DOI: 10.12927/hcpol.2023.27156.

References
1.
. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule. Fed Regist. 1999; 63(231):66631-72. View
2.
Gay F, Clark A . ON THE MODE OF ACTION OF SULFANILAMIDE IN EXPERIMENTAL STREPTOCOCCUS EMPYEMA. J Exp Med. 2009; 66(5):535-48. PMC: 2133572. DOI: 10.1084/jem.66.5.535. View
3.
TAUSSIG H . Thalidomide--a lesson in remote effects of drugs. Am J Dis Child. 1962; 104:111-3. DOI: 10.1001/archpedi.1962.02080030113001. View
4.
Wilson J . An update on the therapeutic orphan. Pediatrics. 1999; 104(3 Pt 2):585-90. View
5.
Laughon M, Avant D, Tripathi N, Hornik C, Cohen-Wolkowiez M, Clark R . Drug labeling and exposure in neonates. JAMA Pediatr. 2013; 168(2):130-6. PMC: 3927948. DOI: 10.1001/jamapediatrics.2013.4208. View